Exchange: NASDAQ·Updated 07:56 PM EDT
ABSI logo

ABSIAbsci Corp

$11.62
$0.51
(4.59%)
Today
Closed $11.62
$0.1007
(0.87%)
After Hours
EarningsAug 14
Mkt Cap$1.97B
Vol5.28M
News
all
press releases
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy
Does Absci Corporation (ABSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
News Placeholder
More News
News Placeholder
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.
Zacks
News Placeholder
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
News Placeholder
Why Did UAL, GLW, ABSI Stocks Surge To 52-Week Highs Today?
Positive clinical data, demand for AI infrastructure, and lower fuel costs drove the rally.
Stocktwits
News Placeholder
ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise
Absci Corporation said that its drug ABS-201 was well-tolerated and showed a long-lasting presence in the body in a clinical trial.
Stocktwits
News Placeholder
Wednesday's ETF Movers: ARKG, SLVR
In trading on Wednesday, the ARK Genomic Revolution ETF is outperforming other ETFs, up about 7.9% on the day. Components of that ETF showing particular strength include shares of Absci, up about 38.3% and shares of Adaptive Biotechnologies, up about 13.7% on the day. And unde...
Nasdaq News: Markets
News Placeholder
Parabolic Surge Sparks Chaos and Could Trap Short Sellers
Investors looking for companies that are delivering tangible catalysts, rather than distant promises, will like today’s list, which spans from brain cancer therapies advancing internationally to AI-designed biologics, home healthcare technologies, one of the largest humanoid robotics transactions of the year, and a good old burger play. Several of these stories are entering catalyst-rich periods that could define the second half of 2026. $WEN, $NTHI, $ABSI, $PLSM, $FRTT, $RUN, $TSLA, $CCXI
24-7 Market News
News Placeholder
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program
Absci reported positive interim Phase 1 ABS-201 data and priced a $100 million stock offering to advance development.read more...
Benzinga
News Placeholder
Absci’s One-Two Punch: Positive Data And $100 Million In Fresh Capital
Artificial intelligence has become one of the most closely watched themes in biotechnology, but investors are increasingly looking for companies that can translate AI-driven discovery into tangible clinical results. This week, Absci (NASDAQ:ABSI) delivered a significant update on both fronts, reporting positive interim Phase 1 data for its lead candidate ABS-201 while simultaneously securing a $100 million financing backed by some of the healthcare sector’s most prominent strategic and institutional investors.
24-7 Market News
News Placeholder
Is Absci Corporation (ABSI) A Good Stock To Buy Now?
Is Absci Corporation (ABSI) A Good Stock To Buy Now...
Yahoo! Finance: News
<
1
2
...
>

Advertisement|Remove ads.